FDA approves subcutaneous Leqembi for early Alzheimer’s, enabling once‑weekly dosing
Executive summary: FDA approved a supplemental BLA for lecanemab‑irmb (Leqembi Iqlik) as a once‑weekly subcutaneous injection for early Alzheimer’s disease. The approval provides a more convenient dosing route, which could increase patient adherence and broaden the drug’s market reach.
Who is involved: Eisai Co., Ltd., BioArctic AB, and the U.S. Food and Drug Administration.
Likely next: Eisai is expected to announce pricing, launch timing, and distribution plans for the subcutaneous formulation in the coming months.
On July 14, 2026, the U.S. Food and Drug Administration approved a supplemental biologics license application for lecanemab‑irmb (Leqembi Iqlik) administered as a once‑weekly subcutaneous injection for early Alzheimer’s disease. The approval expands dosing options beyond the existing intravenous formulation, potentially improving patient convenience and adherence. Eisai, BioArctic’s partner, announced the decision, noting that the subcutaneous formulation showed comparable efficacy and safety to the IV version in clinical data presented at AAIC 2026. The decision may influence future subcutaneous biologic approvals in neurodegenerative disease.
Timeline
- — FDA approves Leqembi Iqlik® (lecanemab‑irmb) subcutaneous injection as a starting dose for early Alzheimer's disease (PR Newswire)
- — New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease (PR Newswire)
Analysis — what this means
Sectors affected
- Alzheimer's disease therapeutics
- biopharmaceutical manufacturing
- neurology drug delivery
Regulatory implications
- FDA’s approval of subcutaneous lecanemab establishes a precedent for subcutaneous delivery of anti‑amyloid antibodies in neurodegenerative disease.
- May influence future subcutaneous BLA submissions for similar biologics, potentially streamlining regulatory pathways.
Historical parallels
- FDA approval of subcutaneous trastuzumab (Herceptin Hylecta) for HER2‑positive breast cancer in 2019.
- FDA approval of subcutaneous rituximab (Rituxan Hycela) for non‑Hodgkin lymphoma and chronic lymphocytic leukemia in 2017.
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped